Fundraising Fox
/Companies
Sign in

Tocagen

San Diego, US · Founded 2007 · Delaware corporation · 1 known investors

Find your way into Tocagen

Sign up to find every way you can get introduced to Tocagen

  • Your email: who you already know at Tocagen, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tocagen team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Tocagen is a clinical-stage biotechnology company developing cancer-selective gene therapies designed to activate a patient's immune system against their own cancer. Its lead product candidate, Toca 511 & Toca FC, is being studied in a global Phase 3 trial for patients with brain cancer.

BiotechHealthtech

Founders & leadership

Tocagen was founded in 2007 by Harry Gruber.

HG
Harry GruberFounder
TD
Thomas DarcyExecutive
DB
Dennis BermanExecutive
DJ
Douglas JollyNamed on SEC filing

Board

FH
Faheem HasnainBoard director
LK
Lori KunkelBoard director
DR
David R. ParkinsonDirector, Board of Directors2015–2020Investor at ESSA Pharma
PS
Paul SchimmelBoard director
FM
Franklin M. BergerBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$83.3M disclosed across 4 rounds · 2012–2023

▶$25MraisedAug 2023 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Antony RileyExecutive Officer
  • Stephen DobersteinDirector
  • Scott BrunDirector
  • Lawrence EichenfieldDirector
  • Hubert ChenExecutive Officer
  • Steven KornfeldDirector
  • David GryskaDirector
  • Barbara FinkDirector
  • Donald WilliamsDirector
  • Paul WagnerExecutive Officer, Director
Offering amount
$25M
Amount sold
$25M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.9MraisedMar 2017 · 107 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas DarcyExecutive Officer, Director
  • Faheem HasnainDirector
  • Harry GruberExecutive Officer, Director
  • Mark FolettaExecutive Officer
  • Douglas JollyExecutive Officer
  • David R. ParkinsonDirector
  • Franklin M. BergerDirector
  • Lori KunkelDirector
  • Dennis BermanExecutive Officer, Director
  • Martin J DuvallExecutive Officer, Director
  • Paul SchimmelDirector
Offering amount
$13M
Amount sold
$10.9M
First sale
Nov 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$46.2MraisedOct 2015 · 250 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas DarcyExecutive Officer, Director
  • Dennis BermanExecutive Officer, Director
  • Faheem HasnainDirector
  • Harry GruberExecutive Officer, Director
  • Lori KunkelDirector
  • Douglas JollyExecutive Officer
  • David R. ParkinsonDirector
  • Paul SchimmelDirector
  • Franklin M. BergerDirector
Offering amount
$50.4M
Amount sold
$46.2M
Minimum investment
$10.5K
Sales commissions
$14K
Placement agents
Newbridge Securities Corporation
First sale
May 2013
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedMar 2012 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dennis BermanExecutive Officer, Director
  • Douglas JollyExecutive Officer
  • Harry GruberExecutive Officer, Director
  • Thomas DarcyExecutive Officer, Director
Offering amount
$5M
Amount sold
$1.1M
Minimum investment
$200K
First sale
Feb 2012
Incorporated
Corporation, Delaware, 2007
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$224.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$269K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Tocagen do?
Tocagen is a clinical-stage biotechnology company developing cancer-selective gene therapies designed to activate a patient's immune system against their own cancer. Its lead product candidate, Toca 511 & Toca FC, is being studied in a global Phase 3 trial for patients with brain cancer.
Who founded Tocagen?
Tocagen was founded by Harry Gruber in 2007.
Who are Tocagen's investors?
Tocagen's investors include BioBrit.
How much funding has Tocagen raised?
Tocagen has disclosed $83.3M raised across 4 rounds.
Where is Tocagen headquartered?
Tocagen is headquartered in San Diego, US.